venBio

2016
12FEB

Apellis Completes $47 Million Series D Financing

posted by admin in Latest News

2015
12AUG

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment For Development of Novel Immuno-Oncology Product Platform

posted by admin in Latest News

2015
05AUG

Metacrine Raises $36M in VC Funding, Focuses on Metabolic Diseases

posted by admin in Latest News

2015
11MAY

Precision BioSciences Lands $26M for Gene-Editing Technology

posted by admin in Latest News

2014
02JUL

VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

posted by admin in Latest News

2014
01JUL

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

posted by admin in Latest News

2014
10JUN

As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund

posted by admin in Latest News

2014
03JUN

Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise

posted by admin in Latest News

2014
17APR

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

posted by admin in Latest News

2013
17OCT

UPDATED: Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff

posted by admin in Latest News

2013
03JUN

Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.

posted by admin in Latest News

2013
04JAN

Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego

posted by admin in Latest News

2013
03JAN

Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer

posted by admin in Latest News

2012
04OCT

Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers

posted by admin in Latest News

venBio

News

News

Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia

Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy

venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough

Apellis Pharmaceuticals Announces Positive Data from APL-2 Studies Showing Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating Officer

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

IMPEL NEUROPHARMA ANNOUNCES $36M FUNDING TO ADVANCE NOVEL DRUG DELIVERY PLATFORM

Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH

Metacrine Announces Appointment of Dr. Ken Song as President and Chief Executive Officer

venBio Closes $315 Million Life Sciences Venture Capital Fund

Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist

Baxalta and Precision BioSciences form Global Genome Editing Collaboration in Immuno-Oncology

Heart Metabolics Announces Multiple Senior Appointments to Management Team

Apellis Completes $47 Million Series D Financing

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment For Development of Novel Immuno-Oncology Product Platform

Metacrine Raises $36M in VC Funding, Focuses on Metabolic Diseases

Precision BioSciences Lands $26M for Gene-Editing Technology

VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund

Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

UPDATED: Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff

Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.

Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego

Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer

Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers